Featured Research

from universities, journals, and other organizations

Benefits of HIV drugs rise, but less than previously believed

Date:
July 22, 2012
Source:
Perelman School of Medicine at the University of Pennsylvania
Summary:
The percentage of HIV patients taking antiretroviral drugs who experienced the full benefit of the drugs jumped from 45 percent of 72 percent during the past decade, a figure that is lower than previous estimates. The findings are considered important for HIV prevention efforts since patients whose virus is in tight control are less likely to transmit the infection to others.

The percentage of HIV patients taking antiretroviral drugs who experienced the full benefit of the drugs jumped from 45 percent of 72 percent during the past decade, a figure that is lower than previous estimates. The findings, considered important for HIV prevention efforts, since patients whose virus is in tight control are less likely to transmit the infection to others, are published this week in JAMA by a team of researchers led by the Perelman School of Medicine at the University of Pennsylvania and Johns Hopkins University School of Medicine. The issue's publication coincides with AIDS 2012, the annual international AIDS conference, being held in the United States for the first in over 20 years this week in Washington, D.C.

Related Articles


The researchers analyzed 32,483 HIV-infected patients cared for in 12 clinics across the United States between 2001 and 2010. patients in the U.S. During that time, the percentage of patients taking antiretroviral drugs who exhibited sustained viral suppression -- having no detectable HIV virus in the blood every time the virus is measured -- increased from 45 percent to 72 percent. The authors point to new drugs and fixed dose combination tablets as factors in improving the efficacy and safety of antiretroviral drug regimens, as well as decreased side effects that make patients more likely to adhere to their treatment. Better access to care during this time period may also be a contributor to the improved viral suppression rates observed in the study.

Despite this increase, the number of patients with tightly controlled HIV infection was significantly less than the 77 percent to 87 percent figures reported in prior studies, which were based on one-time only measures of HIV virus in the blood, rather than considering every time the virus was measured. According to the study's lead investigator, Baligh Yehia, MD, MSHP, MPP, a fellow in the division of Infectious Diseases at Penn Medicine and HIV specialist, "if the HIV virus is not fully suppressed, individuals are at risk of transmitting HIV to others in the community." Yehia says that while significant advances in HIV therapy have occurred over the past decade, consistent adherence to medicines and outpatient care remains a major hurdle for many people living with HIV. The findings come on the heels of the Food and Drug Administration's approval this month of the first drug to prevent HIV infection. Similar to people living with HIV, healthy individuals without HIV infection who chose to take this preventative medication need to have strict drug adherence and frequent HIV testing in order to achieve benefit.

Overall, sustained viral suppression was lower for black patients and injection drug users, while older patients and those with private insurance were the most likely to have sustained viral suppression. "Our analysis showed that HIV care providers need to closely monitor younger patients, African-Americans, injection drug users, and individuals without health insurance to ensure that they have access to HIV drugs and adhere to therapy, since those patients appeared to be least likely to have their infection in tight control," said the study's senior author Kelly Gebo, MD, MPH, an associate professor of medicine at the Johns Hopkins University.

"There is no denying the progress we have made over the past decade," says Yehia, "but, more resources and new technology are needed to ensure that more patients have access to HIV therapy and obtain the full benefits of these drugs."

Funding for the study came from the Agency for Healthcare Research and Quality (AHRQ) (290-01-0012), and the National Institutes of Health (K24 AI073957, K24 DA 00432, R01DA11602, and R01 AA 16893).


Story Source:

The above story is based on materials provided by Perelman School of Medicine at the University of Pennsylvania. Note: Materials may be edited for content and length.


Cite This Page:

Perelman School of Medicine at the University of Pennsylvania. "Benefits of HIV drugs rise, but less than previously believed." ScienceDaily. ScienceDaily, 22 July 2012. <www.sciencedaily.com/releases/2012/07/120722135004.htm>.
Perelman School of Medicine at the University of Pennsylvania. (2012, July 22). Benefits of HIV drugs rise, but less than previously believed. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2012/07/120722135004.htm
Perelman School of Medicine at the University of Pennsylvania. "Benefits of HIV drugs rise, but less than previously believed." ScienceDaily. www.sciencedaily.com/releases/2012/07/120722135004.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins